ATE372980T1 - Benzamid- oder phenylacetamidderivate als liganden der thyroid-rezeptoren - Google Patents

Benzamid- oder phenylacetamidderivate als liganden der thyroid-rezeptoren

Info

Publication number
ATE372980T1
ATE372980T1 AT03763744T AT03763744T ATE372980T1 AT E372980 T1 ATE372980 T1 AT E372980T1 AT 03763744 T AT03763744 T AT 03763744T AT 03763744 T AT03763744 T AT 03763744T AT E372980 T1 ATE372980 T1 AT E372980T1
Authority
AT
Austria
Prior art keywords
ligands
benzamide
thyroid receptors
phenylacetamide derivatives
phenylacetamide
Prior art date
Application number
AT03763744T
Other languages
English (en)
Inventor
Neeraj Garg
Mahmoud Gadim
Thomas Norin
Lars Malm
Denis Ryono
Original Assignee
Karobio Ab
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karobio Ab, Bristol Myers Squibb Co filed Critical Karobio Ab
Application granted granted Critical
Publication of ATE372980T1 publication Critical patent/ATE372980T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03763744T 2002-07-10 2003-07-08 Benzamid- oder phenylacetamidderivate als liganden der thyroid-rezeptoren ATE372980T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0215978.8A GB0215978D0 (en) 2002-07-10 2002-07-10 Novel compounds

Publications (1)

Publication Number Publication Date
ATE372980T1 true ATE372980T1 (de) 2007-09-15

Family

ID=9940187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03763744T ATE372980T1 (de) 2002-07-10 2003-07-08 Benzamid- oder phenylacetamidderivate als liganden der thyroid-rezeptoren

Country Status (20)

Country Link
US (1) US7153997B2 (de)
EP (2) EP1862450A2 (de)
JP (1) JP2005538076A (de)
KR (1) KR20050053590A (de)
CN (1) CN100347152C (de)
AT (1) ATE372980T1 (de)
AU (1) AU2003250908A1 (de)
BR (1) BR0312655A (de)
CA (1) CA2492046A1 (de)
DE (1) DE60316312T2 (de)
GB (1) GB0215978D0 (de)
HR (1) HRP20050015A2 (de)
IS (1) IS7649A (de)
MX (1) MXPA05000460A (de)
NO (1) NO20050714L (de)
PL (1) PL374733A1 (de)
RS (1) RS20050017A (de)
RU (1) RU2317287C2 (de)
WO (1) WO2004007430A2 (de)
ZA (1) ZA200500167B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110713A1 (it) * 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
EP2428516A1 (de) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Neue Phosphor enthaltende Thyromimetika
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
GB0406380D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
CN102203130B (zh) * 2010-08-06 2014-06-25 贝达药业股份有限公司 Glp-1衍生物及其应用
KR101898610B1 (ko) 2010-08-31 2018-09-14 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
CN103534232A (zh) * 2011-04-08 2014-01-22 伯拉考成像股份公司 用于制备3,5-二碘-o-[3-碘苯基]-l-酪氨酸的硫酸化衍生物的方法
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EP3634426A4 (de) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. Zusammensetzungen zur behandlung von fibrose
JP2021518403A (ja) 2018-03-22 2021-08-02 バイキング・セラピューティクス・インコーポレイテッド 化合物の結晶形態及び化合物の結晶形態を生成する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE159515T1 (de) * 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel
GB9816935D0 (en) * 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6395784B1 (en) * 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
JP4225791B2 (ja) * 2001-05-18 2009-02-18 キッセイ薬品工業株式会社 肝癌の予防または再発抑制剤

Also Published As

Publication number Publication date
IS7649A (is) 2005-01-14
JP2005538076A (ja) 2005-12-15
NO20050714L (no) 2005-02-10
AU2003250908A1 (en) 2004-02-02
DE60316312T2 (de) 2008-06-05
CN100347152C (zh) 2007-11-07
WO2004007430A3 (en) 2004-02-19
RU2005103406A (ru) 2005-06-27
HRP20050015A2 (en) 2005-08-31
EP1537073B1 (de) 2007-09-12
BR0312655A (pt) 2005-05-24
GB0215978D0 (en) 2002-08-21
WO2004007430A2 (en) 2004-01-22
ZA200500167B (en) 2006-07-26
US7153997B2 (en) 2006-12-26
MXPA05000460A (es) 2005-07-22
CA2492046A1 (en) 2004-01-22
EP1537073A2 (de) 2005-06-08
CN1668579A (zh) 2005-09-14
RU2317287C2 (ru) 2008-02-20
DE60316312D1 (de) 2007-10-25
EP1862450A2 (de) 2007-12-05
RS20050017A (en) 2007-08-03
PL374733A1 (en) 2005-10-31
US20060135614A1 (en) 2006-06-22
KR20050053590A (ko) 2005-06-08

Similar Documents

Publication Publication Date Title
IS7649A (is) Bensamíð- eða fenýlasetamíðafleiður sem nýtast vel sem viðtakabindlar skjaldkirtilshormóns
KR910014350A (ko) 3-아미노피페리딘 유도체 및 관련 질소 함유 헤테로사이클릭 화합물
WO2003094845A3 (en) Pyridine-based thyroid receptor ligands
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
CY1107005T1 (el) Ετεροπολυκυκλικες ενωσεις και οι χρησεις τους ως ανταγωνιστες των μεταβοτροπικων υποδοχέων του γλουταμικου
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
EA200970326A1 (ru) Алкильные производные в качестве метаботропных рецепторов глутамата
UY28144A1 (es) Agentes terapéuticos
UY28101A1 (es) Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2004067482A3 (en) Substituted anilide ligands for the thyroid receptor
EA199901075A1 (ru) Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона роста
WO2004066929A3 (en) Cycloalkyl containing anilide ligands for the thyroid receptor
NO20072060L (no) 2-acylaminotiazolderivater
TW200628437A (en) Aminoindane dopamine D3 receptor antagonists
DE60223506D1 (de) Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
BRPI0410127A (pt) derivados de pirimidina substituìdos
BRPI0512540A (pt) composto de fórmula; método para o tratamento de um distúrbio do sistema nervoso central; composição farmacêutica; método para a determinação do metabolismo de um derivado de (1-arilsulfonil-1h-indol-3-il)etilamina; e uso do composto
BRPI0506814A (pt) composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, processo para preparar uma composição farmacêutica, e, métodos para tratar um indivìduo sofrendo de um distúrbios afetivo, para tratar um indivìduo sofrendo de um distúrbio urinário e para tratar um indivìduo sofrendo de um distúrbio de alimentação
DK1641775T3 (da) 2-pyridinalkynderivater, der er anvendelige til behandling af smerter
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
PA8608601A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
UA80845C2 (en) Fungicidal mixture, a method for controlling fungi pathogenous to rice, seed and the use of compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1537073

Country of ref document: EP

REN Ceased due to non-payment of the annual fee